A development-focused oncology company specializing in first-in-class cancer treatments.
Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. Niiki Pharma’s lead product, NKP-1339 is a first-in-class small molecule that targets the GRP78 pathway. GRP78 is a master regulator of stress and plays a key role in tumor cell survival and resistance. NKP-1339 is close to completing its Phase I trial, with several patients exhibiting long term anti-tumor activity (stable disease or tumor regression). Niiki Pharma’s second product, NKP-2235 is a first-in-class oral small molecule which targets the endoplasmic reticulum. Endoplasmic reticulum is the cell machinery that repairs protein misfolding. NKP-2235 obtained its FDA IND approval in 2011. A Phase I clinical trial of NKP-2335 will begin shortly.